Blockade of glioma proliferation through allosteric inhibition of JAK2

Science Signaling

Volumn 6, Issue 283, 2013, Pages

  He, Kunyan ^a   Qi, Qi ^a   Chan, Chi Bun ^a   Xiao, Ge ^a   Liu, Xia ^b   Tucker Burden, Carol ^a   Wang, Liya ^a   Mao, Hui ^a   Lu, Xiang ^c   McDonald, Frank E ^c   Luo, Hongbo ^d   Fan, Qi Wen ^e   Weiss, William A ^e   Sun, Shi Yong ^a   Brat, Daniel J ^a   Ye, Keqiang ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c EMORY UNIVERSITY   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 PIPERIDINECARBOXYLIC ACID, 4 OXO 3,5 BIS(PHENYL METHYLENE), ETHYL ESTER; ADENOSINE TRIPHOSPHATE; ANGIOGENESIS INHIBITOR; CASEIN KINASE II; EPIDERMAL GROWTH FACTOR RECEPTOR; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; LESTAURTINIB; LIGAND; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; STAT3 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; ASTROCYTE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; TUMOR VOLUME; XENOGRAFT;

ALLOSTERIC REGULATION; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE DELETION; GLIOMA; HETEROGRAFTS; HUMANS; JANUS KINASE 2; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEURAL STEM CELLS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84880899903     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2003900     Document Type: Article

References (47)

1. B. K. Rasheed, R. N. Wiltshire, S. H. Bigner, D. D. Bigner, Molecular pathogenesis of malignant gliomas. Curr. Opin. Oncol. 11, 162-167 (1999). (Pubitemid 29229607)
2. N. Sugawa, A. J. Ekstrand, C. D. James, V. P. Collins, Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc. Natl. Acad. Sci. U.S.A. 87, 8602-8606 (1990).
3. D. E. Levy, J. E. Darnell Jr., STATs: Transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 3, 651-662 (2002). (Pubitemid 34987786)
4. G. W. Reuther, JAK2 activation in myeloproliferative neoplasms: A potential role for heterodimeric receptors. Cell Cycle 7, 714-719 (2008). (Pubitemid 351520031)
5. J. N. Ihle, D. G. Gilliland, Jak2: Normal function and role in hematopoietic disorders. Curr. Opin. Genet. Dev. 17, 8-14 (2007). (Pubitemid 46109298)
6. J. E. Darnell Jr., STATs and gene regulation. Science 277, 1630-1635 (1997). (Pubitemid 27446219)
7. H. W. Lo, S. C. Hsu, W. Xia, X. Cao, J. Y. Shih, Y. Wei, J. L. Abbruzzese, G. N. Hortobagyi, M. C. Hung, Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res. 67, 9066-9076 (2007). (Pubitemid 47535891)
8. N. de la Iglesia, S. V. Puram, A. Bonni, STAT3 regulation of glioblastoma patho-genesis. Curr. Mol. Med. 9, 580-590 (2009).
9. M. Benekli, H. Baumann, M. Wetzler, Targeting signal transducer and activator of transcription signaling pathway in leukemias. J. Clin. Oncol. 27, 4422-4432 (2009).
10. X. Y. Fu, From PTK-STAT signaling to caspase expression and apoptosis induction. Cell Death Differ. 6, 1201-1208 (1999).
11. J. F. Bromberg, M. H. Wrzeszczynska, G. Devgan, Y. Zhao, R. G. Pestell, C. Albanese, J. E. Darnell Jr., Stat3 as an oncogene. Cell 98, 295-303 (1999). (Pubitemid 29380565)
12. S. Huang, Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: Clinical implications. Clin. Cancer Res. 13, 1362-1366 (2007). (Pubitemid 46450423)
13. H. W. Lo, X. Cao, H. Zhu, F. Ali-Osman, Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin. Cancer Res. 14, 6042-6054 (2008).
14. A. M. Omuro, S. Faivre, E. Raymond, Lessons learned in the development of targeted therapy for malignant gliomas. Mol. Cancer Ther. 6, 1909-1919 (2007). (Pubitemid 47052481)
15. I. K. Mellinghoff, M. Y. Wang, I. Vivanco, D. A. Haas-Kogan, S. Zhu, E. Q. Dia, K. V. Lu, K. Yoshimoto, J. H. Huang, D. J. Chute, B. L. Riggs, S. Horvath, L. M. Liau, W. K. Cavenee, P. N. Rao, R. Beroukhim, T. C. Peck, J. C. Lee, W. R. Sellers, D. Stokoe, M. Prados, T. F. Cloughesy, C. L. Sawyers, P. S. Mischel, Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353, 2012-2024 (2005). (Pubitemid 41609094)
16. Q. Qi, K. He, M. H. Yoo, C. B. Chan, X. Liu, Z. Zhang, J. J. Olson, G. Xiao, L. Wang, H. Mao, H. Fu, H. Tao, S. S. Ramalingam, S. Y. Sun, P. S. Mischel, K. Ye, Acridine yellow G blocks glioblastoma growth via dual inhibition of epidermal growth factor receptor and protein kinase C kinases. J. Biol. Chem. 287, 6113-6127 (2012).
17. M. Y. Wang, K. V. Lu, S. Zhu, E. Q. Dia, I. Vivanco, G. M. Shackleford, W. K. Cavenee, I. K. Mellinghoff, T. F. Cloughesy, C. L. Sawyers, P. S. Mischel, Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res. 66, 7864-7869 (2006). (Pubitemid 44299148)
18. V. K. Srivastava, R. K. Gara, M. L. Bhatt, D. P. Sahu, D. P. Mishra, Centchroman inhibits proliferation of head and neck cancer cells through the modulation of PI3K/ mTOR pathway. Biochem. Biophys. Res. Commun. 404, 40-45 (2011).
19. T. Yamauchi, K. Ueki, K. Tobe, H. Tamemoto, N. Sekine, M. Wada, M. Honjo, M. Takahashi, T. Takahashi, H. Hirai, T. Tushima, Y. Akanuma, T. Fujita, I. Komuro, Y. Yazaki, T. Kadowaki, Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone. Nature 390, 91-96 (1997). (Pubitemid 27494763)
20. E. O. Hexner, C. Serdikoff, M. Jan, C. R. Swider, C. Robinson, S. Yang, T. Angeles, S. G. Emerson, M. Carroll, B. Ruggeri, P. Dobrzanski, Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 111, 5663-5671 (2008).
21. T. A. Wallace, P. P. Sayeski, Jak2 tyrosine kinase: A mediator of both housekeeping and ligand-dependent gene expression? Cell Biochem. Biophys. 44, 213-222 (2006). (Pubitemid 43172319)
22. Q. W. Fan, C. Cheng, Z. A. Knight, D. Haas-Kogan, D. Stokoe, C. D. James, F. McCormick, K. M. Shokat, W. A. Weiss, EGFR signals to mTOR through PKC and independently of Akt in glioma. Sci. Signal. 2, ra4 (2009).
23. X. Pang, L. Zhang, L. Lai, J. Chen, Y. Wu, Z. Yi, J. Zhang, W. Qu, B. B. Aggarwal, M. Liu, 1'-Acetoxychavicol acetate suppresses angiogenesis-mediated human prostate tumor growth by targeting VEGF-mediated Src-FAK-Rho GTPase-signaling pathway. Carcino-genesis 32, 904-912 (2011).
24. N. Sheibani, W. A. Frazier, Thrombospondin-1, PECAM-1, and regulation of angio-genesis. Histol. Histopathol. 14, 285-294 (1999).
25. P. Carmeliet, VEGF as a key mediator of angiogenesis in cancer. Oncology 69 (Suppl. 3), 4-10 (2005). (Pubitemid 41680947)
26. G. Niu, K. L. Wright, M. Huang, L. Song, E. Haura, J. Turkson, S. Zhang, T. Wang, D. Sinibaldi, D. Coppola, R. Heller, L. M. Ellis, J. Karras, J. Bromberg, D. Pardoll, R. Jove, H. Yu, Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21, 2000-2008 (2002). (Pubitemid 34270888)
27. D. Mulliner, D. Wondrousch, G. Schüürmann, Predicting Michael-acceptor reactivity and toxicity through quantum chemical transition-state calculations. Org. Biomol. Chem. 9, 8400-8412 (2011).
28. C. Mazière, M. A. Conte, J. C. Mazière, Activation of JAK2 by the oxidative stress generated with oxidized low-density lipoprotein. Free Radic. Biol. Med. 31, 1334-1340 (2001).
29. R. K. Monroe, S. W. Halvorsen, Cadmium blocks receptor-mediated Jak/STAT signaling in neurons by oxidative stress. Free Radic. Biol. Med. 41, 493-502 (2006). (Pubitemid 44037283)
30. S. Filosto, E. M. Khan, E. Tognon, C. Becker, M. Ashfaq, T. Ravid, T. Goldkorn, EGF receptor exposed to oxidative stress acquires abnormal phosphorylation and aberrant activated conformation that impairs canonical dimerization. PloS One 6, e23240 (2011).
31. J. R. Roberts, C. F. Shaw III, Inhibition of erythrocyte selenium-glutathione peroxidase by auranofin analogues and metabolites. Biochem. Pharmacol. 55, 1291-1299 (1998). (Pubitemid 28206719)
32. H. S. Kwak, H. S. Yim, P. B. Chock, M. B. Yim, Endogenous intracellular glutathionyl radicals are generated in neuroblastoma cells under hydrogen peroxide oxidative stress. Proc. Natl. Acad. Sci. U.S.A. 92, 4582-4586 (1995).
33. C. Erlichman, M. Hidalgo, J. P. Boni, P. Martins, S. E. Quinn, C. Zacharchuk, P. Amorusi, A. A. Adjei, E. K. Rowinsky, Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J. Clin. Oncol. 24, 2252-2260 (2006). (Pubitemid 46630654)
34. D. Laheru, G. Croghan, R. Bukowski, M. Rudek, W. Messersmith, C. Erlichman, R. Pelley, A. Jimeno, R. Donehower, J. Boni, R. Abbas, P. Martins, C. Zacharchuk, M. Hidalgo, A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer. Clin. Cancer Res. 14, 5602-5609 (2008).
35. S. Kasper, F. Breitenbuecher, Y. Hoehn, F. Heidel, D. B. Lipka, B. Markova, C. Huber, T. Kindler, T. Fischer, The kinase inhibitor LS104 induces apoptosis, enhances cyto-toxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukemia. Leuk. Res. 32, 1698-1708 (2008).
36. D. B. Lipka, L. S. Hoffmann, F. Heidel, B. Markova, M. C. Blum, F. Breitenbuecher, S. Kasper, T. Kindler, R. L. Levine, C. Huber, T. Fischer, LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells. Mol. Cancer Ther. 7, 1176-1184 (2008).
37. Y. Dong, B. Lu, X. Zhang, J. Zhang, L. Lai, D. Li, Y. Wu, Y. Song, J. Luo, X. Pang, Z. Yi, M. Liu, Cucurbitacin E, a tetracyclic triterpenes compound from Chinese medicine, inhibits tumor angiogenesis through VEGFR2-mediated Jak2-STAT3 signaling pathway. Carcinogenesis 31, 2097-2104 (2010).
38. C. K. Goldman, J. Kim, W. L. Wong, V. King, T. Brock, G. Y. Gillespie, Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: A model of glioblastoma multiforme pathophysiology. Mol. Biol. Cell 4, 121-133 (1993). (Pubitemid 23071308)
39. K. Clarke, K. Smith, W. J. Gullick, A. L. Harris, Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway. Br. J. Cancer 84, 1322-1329 (2001). (Pubitemid 32522099)
40. F. Ciardiello, R. Caputo, R. Bianco, V. Damiano, G. Fontanini, S. Cuccato, S. De Placido, A. R. Bianco, G. Tortora, Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyro-sine kinase inhibitor. Clin. Cancer Res. 7, 1459-1465 (2001). (Pubitemid 32708703)
41. N. Pore, Z. Jiang, A. Gupta, G. Cerniglia, G. D. Kao, A. Maity, EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res. 66, 3197-3204 (2006).
42. A. K. Larsen, D. Ouaret, K. El Ouadrani, A. Petitprez, Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis. Pharmacol. Ther. 131, 80-90 (2011).
43. Q. W. Fan, Z. A. Knight, D. D. Goldenberg, W. Yu, K. E. Mostov, D. Stokoe, K. M. Shokat, W. A. Weiss, A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9, 341-349 (2006). (Pubitemid 43668732)
44. T. N. Kreisl, A. B. Lassman, P. S. Mischel, N. Rosen, H. I. Scher, J. Teruya-Feldstein, D. Shaffer, E. Lis, L. E. Abrey, A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J. Neurooncol. 92, 99-105 (2009).
45. D. A. Reardon, A. Desjardins, J. J. Vredenburgh, S. Gururangan, A. H. Friedman, J. E. Herndon II, J. Marcello, J. A. Norfleet, R. E. McLendon, J. H. Sampson, H. S. Friedman, Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J. Neurooncol. 96, 219-230 (2010).
46. Y. Zhan, D. M. O'Rourke, SHP-2-dependent mitogen-activated protein kinase activation regulates EGFRvIII but not wild-type epidermal growth factor receptor phosphorylation and glioblastoma cell survival. Cancer Res. 64, 8292-8298 (2004). (Pubitemid 39491767)
47. T. Zhang, J. Ma, X. Cao, Grb2 regulates Stat3 activation negatively in epidermal growth factor signalling. Biochem. J. 376, 457-464 (2003). (Pubitemid 38010531)